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Key Points
• Physiology and motor function of the large bowel can be non-invasively measured using magnetic resonance
imaging.
• Using a stimulus such as Moviprep, FC can be differentiated from IBS-C by assessing the motility of AC and
time to first bowel movement.
• The underlying disorder of function differs in FC and IBS-C implying that response to treatments altering
motility will differ.
• MRI can be used as a tool to clarify the underlying functional abnormality in patients with difficult and
resistant constipation.
• Even without MRI, using a 1L of Moviprep as a stimulant and measuring the time to first bowel movement can
assist in differentiating between FC and IBS-C.
Abstract
Background Functional constipation (FC) and irrita-
ble bowel syndrome with constipation (IBS-C) share
many symptoms but underlying mechanisms may be
different. We have developed a magnetic resonance
imaging (MRI) technique to measure intestinal vol-
umes, transit, and motility in response to a laxative,
Moviprep. We aim to use these biomarkers to study
the pathophysiology in IBS-C and FC. Methods
Twenty-four FC and 24 IBS-C were studied. Transit
was assessed using the weighted average position
score (WAPS) of five MRI marker pills, taken 24 h
before MRI scanning. Following baseline scan, partic-
ipants ingested 1 L of Moviprep followed by hourly
scans. Magnetic resonance imaging parameters and
bowel symptoms were scored from 0 to 4 h. Key
ResultsWeighted average position score for FC was 3.6
(2.5–4.2), significantly greater than IBS-C at 2.0 (1.5–
3.2), p = 0.01, indicating slower transit for FC. Func-
tional constipation showed greater fasting small
bowel water content, 83 (63–142) mL vs 39 (15–70)
mL in IBS-C, p < 0.01 and greater ascending colon
volume (AC), 314 (101) mL vs 226 (71) mL in IBS-C,
p < 0.01. FC motility index was lower at 0.055 (0.044)
compared to IBS-C, 0.107 (0.070), p < 0.01. Time to
first bowel movement following ingestion of
Moviprep was greater for FC, being 295 (116–526)
min, compared to IBS-C at 84 (49–111) min, p < 0.01,
and correlated with AC volume 2 h after Moviprep,
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r = 0.44, p < 0.01. Using a cut-off >230 min distin-
guishes FC from IBS-C with low sensitivity of 55% but
high specificity of 95%. Conclusion & Inferences Our
objective MRI biomarkers allow a distinction between
FC and IBS-C.
Keywords colon, functional constipation, irritable
bowel syndrome with constipation, laxative, motility.
Abbreviations: AC, ascending colon; FC, functional
constipation; HV, healthy volunteer; IBS-C, irritable
bowel syndrome with constipation; IBS, irritable bowel
syndrome; MRI, magnetic resonance imaging; PEG,
polyethylene glycol; PHQ12SS, Patient Health Ques-
tionnaire 12 Somatic Symptom scale; SBWC, small
bowel water content; TTFBM, time to first bowel
movement; VAS, visual analogue scale; WAPS,
weighted average position score.
INTRODUCTION
Constipation is a common condition with up to 27% of
the population reporting suffering from constipation at
least some of the time.1 The commonest complaints
reported are straining to pass stool, gas, and hardness of
stool followed by infrequent bowel movements. About
half of the patients also complain of abdominal pain.2
Abdominal pain/discomfort is a key feature of irritable
bowel syndrome with constipation (IBS-C) which dis-
tinguishes it from functional constipation (FC) inwhich
pain is either absent or not prominent.3 The other
symptoms of these two conditions like hard stools and
straining overlap extensively and if one suspends the
requirement for FCpatients to not have IBS, then 44%of
patientswith FC alsomeet Rome III IBS-C criteriawhile
85%of IBS-Cmeet thecriteria forFC.4However,making
the distinction in some patients may be worthwhile
since, as we show below, the underlying pathophysiol-
ogy and response to treatments in chronic constipation
and IBS-C appear to differ in important ways.
Motility also appears to differ in the few studies
available. Prolonged (24 h) ambulatory manometry
recordings in FC with severe slow transit have shown
reduced motility5 while one study using radioteleme-
try showed that IBS-C patients had normal or increased
contractions, particularly in the distal quartile of
colonic transit compared to both FC and healthy
controls.6 Current methods of objective assessment of
motility have significant limitations to widespread use
because they are technically demanding and require
expensive equipment and special expertise to operate.
The need for bowel cleansing for both ambulatory
manometry and rectal barostat testing significantly
alters the underlying pathology and the techniques
introduce many other variables including psychologi-
cal distress. Furthermore, not all patients will agree to
such invasive tests making the observations biased in
unpredictable ways. There is therefore an unmet need
for a more acceptable assessment.
We have recently developed a non-invasive magnetic
resonance imaging (MRI) technique which allows
measurement of intestinal water content,7 colonic
volumes,8 motility,9 and transit10 in a way acceptable
to most patients.
The aim of this study was to combine these measure-
ments to create a test of colonic function using as our
standardized intervention a large dose of the osmotic
laxative, Moviprep (a combination of PEG and elec-
trolyte) to distend the whole colon and allow observa-
tion of the colonic response. We hypothesized that this
response would differ in FC compared to IBS-C.
MATERIALS AND METHODS
This was an open-label study examining the response of the
small and large intestine to acute ingestion of 1 L of poly-
ethylene glycol (PEG) and electrolyte solution (Moviprep,
Norgine Pharmaceuticals Ltd, Harefield, UK). We used a virtu-
ally identical protocol to that already reported in healthy
controls (HV)11 from which we derived our normal range. These
studies were approved by the National Research Ethics Service,
United Kingdom (10/H0906/50 and 11/EM/0440) and by the
Medicines and Healthcare products Regulatory Agency (MHRA
CTA reference number 03057/0045/001-0002). This study was
registered with the ClinicalTrials.gov (Identifier NCT01622972)
and the EU clinical trials register with EudraCT number 2010-
021879-85. There were no changes to the protocols from that
published at registration. All participants gave written informed
consent and the studies were carried out according to the Good
Clinical Practice principles.
Subjects
Forty-eight (45 females, 3 males, 21–68 years old) patients with
chronic constipation were recruited from gastroenterology clinics
in the Nottingham University Hospital Trusts, Nottingham
during March 2012 to February 2014. These comprised two groups
classified according to the Rome III criteria into FC or irritable
bowel syndrome with predominant constipation (IBS-C).3
Twenty-four patients had FC and 24 patients had IBS-C. As this
was a secondary referral practice, these patients had all failed at
least one simple laxative in the past before entry into the study.
Participants were required to stop any laxatives and medications
that could affect the gut motility approximately 7 days prior to
the allocated study day. Participants who had other chronic
gastrointestinal illness, gastrointestinal surgery (except appen-
dicectomy), or diabetes were excluded from the study. Other
exclusion criteria were pregnancy and being unwilling to stop any
medications that interfere with gastrointestinal function includ-
ing opiates. All participants completed a safety questionnaire to
exclude contraindications to MRI such as metal implants in the
body. They also all completed the Hospital Anxiety and Depres-
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sion questionnaire and Patient Health Questionnaire 12 Somatic
Symptom scale (PHQ12SS) to assess psychological and somatic
distress.
Study design
The constipation patients followed the same protocol as a
previous healthy volunteer (HV) study11 but in addition, they
also had a MRI assessment of the whole gut transit time which
required them to swallow five MRI marker pills (20 mm 9 7 mm)
at 8 AM, which were imaged 24 h later at the beginning of the
study day. The MRI marker pills were used to calculate a
weighted average position score (WAPS) depending on their
position in the bowel. This method of WAPS using the magnetic
resonance imaging, which is similar in concept to the well-
validated Mayo technique using scintigraphy after a single dose of
isotope marker,12 has been validated against the standard radio-
opaque marker test.10,13 The patients were required to fast
overnight before the study day. Following their baseline scans to
assess the location of the transit markers in the gut and make
baseline volume measurements (see MRI scanning protocol), they
ingested 1 L of Moviprep containing 100 g PEG (mean molecular
weight 3350 Da), Na+ 182, K+ 14, Cl 60, SO4 53, ascorbate
30 mEq within 60 min, before undergoing hourly MRI scans for
4 h. We were able to reduce the scanning time to 4 h as our HV
results11 indicated that all the important responses could be
observed within this time. Patients completed paper bowel
symptom questionnaires and stool diaries throughout the study.
The paper bowel symptom questionnaire required subjects to
indicate on a 10-cm visual analogue scale (VAS) scale the severity
of each of the following symptoms: abdominal pain, bloating,
abdominal distension, abdominal fullness, and nausea. They were
required to complete this questionnaire every hour immediately
following each MRI scan in order to correlate these symptoms
with the MRI findings. They also filled out a paper stool diary
recording each bowel movement using the Bristol Stool Form
Scale14 and baseline symptoms for 1 week before the study day
while they were off any medications that might affect gastroin-
testinal symptoms, during the study day and for 6 days after the
study day. Particular note was made of the time to first defecation
following ingestion of Moviprep. Patients were allowed to drink
water ad libitum 120 min after completing Moviprep ingestion.
MRI scanning protocol
All MRI scans were carried out with a 1.5T Philips Achieva
scanner (Philips, Best, The Netherlands), using a 16-channel XL
torso coil. All participants were scanned in a supine position for
approximately 15 min and while between scans they were sat in
an up-right position in the waiting room. A turbo spin echo single
shot sequence (TR/TE = 8000/320 ms, FA = 90°, FOV = 400
9 362 9 168 mm3, ACQ res = 1.56 9 2.90 9 7.0 mm3) was used
to acquire T2-weighted coronal images for measurement of small
bowel water content (SBWC) as previously validated7 and shown
to be responsive to interventions.7,15,16 This sequence gives high-
intensity signals from areas with free fluid and little signal from
body tissues. Assessment of WAPS involved the acquisition of
two sequences, which were obtained as coronal sections, collected
at two stations with a 30-mm overlap. Firstly, a T1-weighted 3D
Turbo Field Echo sequence was used to count and locate the
number of pills remaining in the colon after 24 h of pill ingestion.
Secondly, a 3D dual echo fast field echo DIXON sequence was
used to confirm the location of the pills, by creating a rotating
movie of the maximum intensity projection of the water-only
images as previously described.10 This movie allowed 3D visual-
ization of the colon and accurate localization of the position of the
pills in the uncommon event that the alternate T1-weighted
image scan was not conclusive. A coronal dual echo fast field echo
sequence (TR/TE1/TE2 = 157/2.3/4.6 ms, FA = 80°,
FOV = 450 9 362 9 168 mm3, ACQ res = 2.01 9 2.87 9 7 mm3)
was used to assess colonic volumes.8 This was performed during
an expiration breath hold of 13 s and a transverse dual echo fast
field echo sequence under a 20 s expiration breath hold. The
Analyze9TM software (Mayo Foundation, Rochester, MN, USA)
was used to manually segment each regional colon volume from
the coronal image slices. Each colon region was identified and a
3D representation of the morphology, from which the volume of
each regional colon was measured, was built (Fig. 1). Lastly,
motility scans of the ascending colon (AC) involved a single
sagittal slice positioned centrally through the AC, using a
balanced turbo field echo sequence (TR/TE = 3/1.5 ms, FA = 70°,
FOV = 330 9 228 9 15 mm3, ACQ res = 1.5 9 1.5 9 15 mm3),
which was scanned repetitively every second for 2 min (cine
MRI) during which time the participants were allowed to breathe
gently. The data were registered using the dual registration of
abdominal motion methodology.9 The registration process first
removes breathing effects from the images and then parameterizes
the motion of the tissue within the images over time to allow
lines and regions of interest to be automatically tracked through
the time series using custom written software in Matlab (The
MathsWorks Inc, Natick, MA, USA). Following registration, an
observer drew a series of lines across the AC on the median image,
perpendicular to the main axis of the AC and with the edges of the
lines touching the colon walls.17 These lines were then automat-
ically propagated through the time series using the information
from image registration. Any changes in line with length
indicated movement of the colonic wall (i.e., a contraction or
expansion of the lumen). A motility index was defined as the
fraction of time points, summed across all lines drawn (line length
smoothed to reduce noise) which had a rate of change in line
length (i.e., wall velocity) between consecutive time points of
more than 0.5 mm/s. Hereafter this is referred to as line analysis
0.5mm/s index.
17 This index had been validated against observer
measurements of wall motion11 and has an excellent correlation
with observer scoring across a wide range of colonic motility.17
Sensitivity to distension was assessed by dividing bloating score at
the time of peak distension (120 min from start of Moviprep
ingestion) by the simultaneously recorded total colonic volumes.
Repeatability, inter-observer variability, and
normal ranges
All our images were analyzed by an operator blind to the patient
details to avoid bias. Using our standard techniques the inter-
observer variability for colonic volumes is 5% (Pritchard SE et al.
unpublisheddata).8Forcolonictransit, the inter-observervariability
is also good with previously reported intra-class correlation coeffi-
cient = 0.78; while in previous studies the day-to-day repeatability
of transit was acceptable with intra-class correlation coefficient of
0.61.10 For the line analysis 0.5mm/s indexofmotility intra- and inter-
observer agreement was excellent, with previously reported intra-
class correlation coefficients of 0.96 and 0.95, respectively.17
We have established that the median WAPS in a group of
healthy volunteers was 0.8 (IQR 0–1.6) based on our previous HV
study.10 We defined the upper limit of normal (ULN) for the
WAPS as exceeding the 95th centile above normal value, that is,
more than 2.2. The normal colonic volumes based on the previous
study8 were 203  75 mL for AC volume, 198  79 mL for
transverse colon volume, and 60  86 mL for descending colon
volumes giving upper limit of normal of 343, 325, and 282 mL,
© 2016 The Authors.
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respectively. The normal SBWC based on our previous study15
was 81 (37–130) mL giving the upper limit normal of 127 mL. The
upper limit of normal for time to first bowel movement in a
cohort of healthy volunteers from our previous study11 was
190 min. The upper limit of normal for sensitivity to distension at
2 h post Moviprep in a cohort of healthy volunteers from our
previous study11 was 5.2/L.
Power and statistical analysis
All statistical analyses were carried out using the GraphPad Prism
version 6.0 for Windows (GraphPad Software, La Jolla, CA, USA).
D’Agostino and Pearson omnibus normality test was used to
assess distribution of data. Normally distributed data are
expressed as mean  SD and non-normally distributed data are
expressed as median (interquartile range; IQR). Normally dis-
tributed data were analyzed using the unpaired t-test, one-way
ANOVA and two-way ANOVA while non-normally distributed data
were analyzed using Mann–Whitney test and Kruskal–Wallis test.
Sample size Our previous study of the effect of another non-
absorbable osmotic laxative mannitol15 gave a mean (SD) change
in SBWC at 40 min postprandially after ingesting 300 mL glucose
of 6 (39.5) mL. Using n = 12, we calculated we could detect an
increase in 55 mL with 90% power which was very much less
than predicted from theoretical considerations which suggest a
change in >1000 mL. We planned to use 24 per group to ensure we
could assess our secondary endpoints for which there are no data
with which to perform a power calculation. There was no
previous study using MRI to assess small and large bowel
motility/function in IBS-C and FC so we were not able to perform
a power calculation for these parameters.
RESULTS
Forty-eight participants were recruited into the study
(for Consort diagram see Fig. S1); however, five did not
complete the study, one due to diarrhea the day before,
three due to withdrawal of consent, and one became
pregnant. Thus, 23 FC and 20 IBS-C were included in
the analysis.
Demographics
Participants were expected to be mostly middle-aged
females with mild anxiety and somatization. There
were no differences in the baseline demographics
between the FC and IBS-C group (Table 1). The usage
of laxative(s) prior to recruitment to the study was
similar in the two groups of patients who used one to
three laxatives, mostly osmotic and stimulatory agents
with 8 and 11, respectively, having tried and failed the
newer prokinetic prucalopride. While baseline abdom-
inal pain in the week preceding the study day tended to
be higher in IBS, this was not statistically significant.
Other baseline symptoms for both groups, particularly
A B
Figure 1 (A) Three-dimensional segmented
colon from (A) a healthy control giving a
total colonic volume of 383 mL and (B) a
functional constipation patient giving a total
colonic volume of 1244 mL.
Table 1 Baseline characteristics for FC and IBS-C patients in the week
preceding the MRI study day
Mean (SD) FC (n = 23) IBS-C (n = 20) p-value
Age 47 (35–51) 39 (27–53) 0.18
Male : female 2 : 21 0 : 20
Anxiety score (range 0–21) 8.5 (5.4) 7.8 (5.4) 0.68
Depression score
(range 0–21)
4.5 (3–12) 4.0 (2.0–6.8) 0.20
PHQ12SS 6.6 (3.9) 7.1 (4.5) 0.74
Values are mean (SD) if normally distributed data and median
(interquartile range) if non-normally distributed data. FC, functional
constipation; IBS-C, irritable bowel syndrome with constipation.
© 2016 The Authors.
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stool frequency and consistency were similar, the only
exception being the significantly higher urgency score
for the IBS-C patients compared to the FC patients
(Table 2).
MRI parameters
Gut transit Weighted average position score exceeded
the ULN in 82% of FC and 47% of IBS-C patients. The
median WAPS was 3.6 (2.5–4.2) for FC, significantly
greater than the 2.0 (1.5–3.2) for IBS-C indicating
slower transit, p = 0.01. When compared with the
healthy volunteers in our previous study,10 both
patient groups showed significantly slower transit,
Kruskal–Wallis test p < 0.01.
Intestinal volumes Small bowel: Fasting SBWC was
above the upper limit of normal for 30% of FC and 15%
IBS-C, the value for FC being significantly higher at 83
(63–142) mL compared to IBS-C 39 (15–70) mL, respec-
tively, p < 0.01 (Fig. S2). Small bowel water content for
bothgroupspeakedat 1 h following the start of ingestion
ofMoviprepbeforedeclining (Fig. 2).Ateachtimepoint
including the fasting baseline, SBWC was significantly
higher in FC compared to IBS-C (Fig. 2). Further SBWC
measurementswerenotconsideredaspatientshadwater
ad libitum after 2 h following ingestion of Moviprep.
Large bowel: Forty-eight percent of FC and 5% of
IBS-C had baseline AC volumes above the upper limit
of normal. These were significantly higher in the FC
group compared to IBS-C group (Table 3 and Fig. 3).
One h following completion of Moviprep, the AC
volumes were significantly increased in the FC group
compared to IBS-C (Table 3 and Fig. 3).
When the total colonic volume was measured, FC
had significantly higher total colonic volume compared
to IBS-C (Table 3). As can be seen in Fig. 4, the total
colonic volume for FC nearly doubled from baseline at
1 h following completion of ingestion of 1 L
Moviprep, and remained significantly higher during
the subsequent 3 h when compared to IBS-C. There
was a significant effect of patient group (p < 0.01) and of
time (p < 0.01), with a significant interaction between
the two (p < 0.01) as shown by two-way ANOVA.
Motility index The motility of the AC based on the
line analysis 0.5mm/s index rose rapidly after Moviprep
Table 2 Baseline abdominal symptom scores during week preceding
the MRI study day
FC IBS-C p-value
Abdominal pain (0–10) 0.71 (0.29–2.29) 1.57 (0.96–1.86) 0.29
Urgency (0–10) 0.14 (0–0.71) 0.32 (0–0.64) 0.04
Bloating (0–10) 1.39 (0.91) 1.69 (0.79) 0.28
Average stool
frequency/week
0.57 (0.29–0.71) 0.64 (0.54–1.0) 0.15
Average stool
consistency (1–7)
2.66 (1.68) 2.57 (1.42) 0.85
Values are mean (SD) if normally distributed data and median
(interquartile range) for non-normally distributed data. FC, functional
constipation; IBS-C, irritable bowel syndrome with constipation.
Figure 2 Small bowel water content (SBWC) in the functional
constipation (FC) and irritable bowel syndrome with constipation (IBS-
C) patient groups during the initial 2 h of the study. The baseline scan
is at time 60 min and the arrow shows the start of Moviprep
ingestion. Time 0 is time of completion of Moviprep ingestion. Small
bowel water content rose significantly over time for FC. FC patients
had significant elevated fasting SBWC at baseline (time 60 min);
p < 0.01, Time 0 after completion of Moviprep; p < 0.01 and 1 h after
completion of Moviprep; p = 0.03, compared to IBS-C.
Table 3 Colonic volumes, motility of ascending colon, and sensitivity
index between FC and IBS-C groups
FC IBS-C p-value
Baseline ascending
colonic volumes (mL)
314 (101) 226 (71) <0.01
Ascending colon volumes
at 120 min
597 (170) 389 (169) <0.01
Baseline total colonic
volumes (mL)
847 (280) 662 (240) 0.03
Total colon volumes
at 120 min
1505 (387) 1039 (418) <0.01
Motility of ascending
colon at 120 min
(line analysis0.5mm/s index)
0.055 (0.044) 0.107 (0.070) <0.01
Values are mean (SD). FC, functional constipation; IBS-C, irritable
bowel syndrome with constipation.
© 2016 The Authors.
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ingestion, but was significantly lower in FC compared
to IBS-C at 120 min from the start of Moviprep
ingestion (Table 3 and Fig. 5).
Bowel habit following stimulation with laxative All
FC patients had fewer bowel movements in the 24-h
period following ingestion of Moviprep than our lower
limit of normal which is 6. Functional constipation
patients had only three (2–5) bowel movements,
significantly less than the IBS-C patients who had
seven (6–10) bowel movements/24 h, p < 0.01. The
time to the first bowel movement following ingestion
of Moviprep was above our upper limit of normal in
60% of FC patients but only 15% of the IBS-C patients.
Mean value was significantly longer in FC group
compared with IBS-C, being 295 (116–526) min and
84 (49–111) min in FC and IBS-C, respectively, p < 0.01
(Fig. S3).
Correlation between time to first bowel
movement after provocation with laxative and
MRI parameters
Those with distended ACs following Moviprep took
longer to open their bowel. Time to first bowel
movement correlated positively with AC volume at
2 h post Moviprep, Spearman r = 0.44, p < 0.01. It
also correlated positively with the fasting SBWC,
Spearman r = 0.34, p = 0.04.
Predictors of symptoms
Symptoms in general correlated poorly with objective
MRI parameters. Bloating was not linked to objective
distension (based on the 10-cm VAS-bloating score
during the study period) moreover sensitivity to
distension at 120 min post Moviprep, showed no
difference between the groups being 4.84 (2.64) and
5.62 (4.40) per L, p = 0.49 for FC and IBS-C, respec-
tively. The sensitivity to distension at 120 min post
Moviprepwas above our upper limit of normal in 55%
of IBS-C patients and 35% of FC patients.
DISCUSSION
This is the first report of an objective, dynamic
assessment of colonic function, performed non-inva-
sively using MRI in chronic constipated patients and as
such provides much new data. Very early studies using
X-ray images had provided anecdotal details of colonic
Figure 3 Ascending colon volumes in functional constipation (FC) and
irritable bowel syndrome with constipation (IBS-C) patients were 314
(101) and 597 (170) mL for FC, and 226 (71) mL and 389 (169) mL for
IBS-C at baseline and 120 min after the start of Moviprep ingestion,
respectively. Both fasting and 120-min values for FC were significantly
greater than IBS-C, both p < 0.01.
Figure 4 Total colonic volumes over time for functional constipation
(FC) and irritable bowel syndrome with constipation (IBS-C) patients.
The time is from completion of Moviprep ingestion. As can be seen,
total colon volumes peaked at 60 min. Two-way ANOVA showed a
significant difference both over time (p < 0.01) and between groups
(p < 0.01), with significantly higher values for FC. The interaction
effect was significant at p < 0.01.
© 2016 The Authors.
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motility and response to eating.18 However, the real-
ization of the dangers of irradiation brought such
studies to an abrupt end. Subsequent studies have
used transit of radio-opaque markers13 and clearance of
isotope from the colon19 as surrogate markers of
motility. These correlate reasonably well with symp-
toms, but of course provide little detail of colonic wall
movements.20
Direct measurement of colonic motility using
manometry has been used in specialist centers but is
technically demanding, requiring bowel preparation,
and colonoscopy to position the tube, which is
unpleasant and carries a small but definite risk for
the patient. Furthermore, given substantial diurnal
variation in colonic motility adequate assessment
requires prolonged (up to 24 h) recording which
imposes a further burden on the patient.5 This has
limited its use despite the exquisite detail it provides.21
Our technique is by contrast extremely easy to
administer and very acceptable to patients. Further-
more, our test is directly related to the symptoms
patients complain of, namely unresponsiveness to
laxatives, and gives a clear indication of the mecha-
nisms underlying constipation.
By providing a large distending stimulus we have
been able to show distinct motor responses which are
impaired in most patients with FC. Most IBS-C
patients in contrast show a normal initial response
but in the latter half of the study this appears to tail
off more rapidly than we expected from our previ-
ously published studies of healthy volunteers.11
Motility was assessed using a validated, automatic
technique that reduces the time to obtain a report
and improves inter-observer variability.17 It will also
make it feasible to analyze longer time periods,
though by using a provocation test with a strong
stimulus such as Moviprep, less time is required
than if waiting for spontaneous contractions, which
are often erratic. Whether these responses are useful
clinically to predict response to therapy requires
further study but anecdotally it is our impression
that those with a hypomotile colon seem to respond
well to prokinetics such as prucalopride while those
with normal or hyperactive colons tend to get pain
and diarrhea.
The observation of colonic volumes in functional
bowel disorders is novel and its full significance still
unclear. Using the MRI to visualize the physiology of
the undisturbed large bowel, we had found that the
fasting AC of patients with FC is significantly larger
than those with IBS-C. When compared with our
previous study, the AC volume in FC [314 (100) mL]
is significantly larger than the healthy controls [202.9
(75.0) mL] and IBS with diarrhea [median 188 (165–251)
mL], Kruskal–Wallis, p < 0.01.8 In contrast there was
no difference in the AC volume in IBS-C when
comparing to similar healthy control, p = 0.21.
Whether treatment will alter resting volumes requires
further study.
Constipation is associated with slow transit22 and
diarrhea with fast whole gut transit23 and accelerated
clearance of the AC,24 but in each case the overlap
with normal is substantial, as is the day to day
variability at around 25%.25 This is undoubtedly
because transit depends on many uncontrolled factors
such as diet, microbiota, psychological factors, and
motility.
A dynamic function test using a large stimulus in a
controlled setting allows us to overcome some of this
background noise and in patients with FC, show a clear
difference from both normal and IBS-C. This is impor-
tant because with the exception of pain and urgency
our FC and IBS-C patients had very similar clinical
features including bloating, infrequent bowel move-
ments, hard stools, and pain. Despite this they have
very different transit and as we show, differing
underlying pathophysiology.
Figure 5 Motility of the ascending colon for functional constipation
(FC) and irritable bowel syndrome with constipation (IBS-C) patients
during the study day. Motility for IBS-C rapidly rose from baseline and
peaked at 120 min from the start of Moviprep ingestion when the
motility for IBS-C was significantly elevated at 0.107 (0.070) compared
to FC 0.055 (0.044), p < 0.01.
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The small bowel has been largely ignored in studies
of constipation in the past because there was no easy
way of assessing its function. Magnetic resonance
imaging provides a new way of addressing its role. We
found the fasting SBWC to be significantly larger in FC
compared to IBS-C suggesting a pan-intestinal defect.
In our previous study by Marciani et al.,15 we found
that patients with diarrhea due to IBS have reduced
fasting SBWC, which may reflect increased tone and
faster orocecal transit time. This may imply that the
larger fasting SBWC seen in our FC group reflects
reduced small bowel tone and prolonged orocecal
transit time, but we did not measure this as our
previous study suggested MRI assessment of OCTT is
less reliable.10
We tried to assess visceral hypersensitivity non-
invasively by looking at symptoms particularly
bloating following the distension of the AC by
Moviprep. Overall visceral hypersensitivity between
the patients (both FC and IBS-C) was significantly
higher compared to healthy volunteers giving a mean
(SD) of 5.2 (3.5) for the patients and 2.0 (1.7) for healthy
volunteers (p < 0.01). Unfortunately there is substan-
tial overlapping between the patient groups, possibly
because the FC group starts from a larger initial
volume, which may make the arrival of large volumes
of fluid more painful than in IBS patients, who start
with a relatively normal AC.
Limitations
An important limitation in our study was the fact that
the WAPS was previously validated in healthy controls
that had a median (IQR) of 0.8 (0–1.6).10 Extrapolating
beyond this range may not be valid and a future
validation study in a cohort of constipated patients will
be required. We did not standardize patients’ diet/fiber
intake prior to the study but in the future this might
reduce the variability in fasting values.
Clinical implications
Our test requires only a standard MRI scanner which is
available in most centers. Its cost compares favorably
with the current alternative way of assessing disor-
dered colonic motility namely manometry. It is also
comparable to the cost of colonoscopy, a test widely
performed in evaluating constipation but which yields
no information about colonic function and is rarely of
value. While currently only available in specialist
centers, its use in very severe cases in whom colec-
tomy or sacral nerve stimulator implantation is
contemplated could be easily justified if it prevents
an IBS-C patient from undergoing unnecessary and
ineffective treatments.
Even for those without access to MRI for such
patients, the Moviprep challenge could be used with-
out imaging, as defecation after ingestion of Moviprep
within 230 min identifies 95% of IBS-C while only
being found in 45% of FC. This is useful because it
should prevent the use of strong stimulant laxatives in
IBS-C, as this can cause further abdominal pain and
suggest that an agent with both laxative and pain-
relieving properties such as Linaclotide or Lubipros-
tone might be a better treatment for this group of
patients.26,27
Even though CC is common, diagnosis of this
condition is mainly based on patient-reported symp-
toms. This can be unreliable as very often there is a
lack of agreement between physician and patients
when defining constipation.3,28 In this study, we were
able to objectively measure intestinal volumes and
colonic motility in patients with chronic constipation.
It is possible that in the future patients could be
categorized by these objective parameters rather than
the current symptom-based classification. This may
allow a better prediction of response to specific treat-
ments.
We have shown that this colonic function test is
patient acceptable, technically undemanding and
shows important differences in colonic physiology
between patients with very similar symptoms. Its use
could contribute to individualizing patient care in
this common but poorly treated condition. Finally,
being non-invasive and involving no ionizing radiation
this test is eminently suitable for evaluating new
treatments for disordered intestinal motility.
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SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher’s web site:
Figure S1 Consort diagram showing recruitment.
Figure S2 Fasting small bowel water content (SBWC) in the functional constipation (FC) and irritable bowel
syndrome with constipation (IBS-C) patient groups as measured using MRI.
Figure S3 Time to first bowel movement (min) following ingestion of Moviprep for functional constipation (FC)
and irritable bowel syndrome with constipation (IBS-C) patients.
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